PIONEERING THE NEXT GENERATION OF CLINICAL LABORATORIES.
PIONEERING THE NEXT GENERATION OF CLINICAL LABORATORIES.
The offering boasts guaranteed revenue with contracts across 7 MSOs that ensure a steady flow of 421,000 tests biannually, translating to an estimated $189.45 million in annual revenue potential. Furthermore, strategic acquisitions bolster this potential; one acquisition includes a Texas lab currently generating $6 million. Additionally, a planned acquisition in North Florida will secure access to crucial payer contracts and expand market reach. Lastly, the initiative includes a strategic market expansion into the southeastern U.S. through the North Florida lab, ensuring broader geographic coverage and enhanced testing capacity. This comprehensive strategy not only promises substantial revenue streams but also positions the company for sustained growth and a stronger market presence.
Our leadership team is a powerhouse of innovation and expertise, poised to drive transformative growth in the healthcare sector. Featuring a co-owner with a robust background in financial management, a CEO who has masterfully steered significant revenue growth through strategic IT and service innovations, a visionary leader who expanded a family business to a $200M entity, and a clinical research veteran with extensive experience in groundbreaking drug development, our team embodies the strategic vision and operational excellence necessary to lead the industry. Their collective expertise and proven track records assure not only the execution of ambitious goals but also a steadfast commitment to setting new industry standards and achieving exceptional results.
Discover an exceptional investment opportunity with a projected company poised for explosive growth in its inaugural year. With strategic implementation of MSO contracts and additional revenue from a Texas lab, the company anticipates generating over $195 million in revenue. Coupled with a robust 35% EBITA margin, the financial forecast predicts a company valuation reaching $204.75 million by the end of Year 1. An initial $30 million investment for a 40% equity stake is expected to burgeon to $81.9 million, offering an impressive 173% ROI. This venture is not just a promising financial endeavor but a gateway to substantial equity value growth, leveraging strategic positioning and high market growth potential.
The opportunity is ripe for strategic investors to capitalize on a lucrative and scalable venture in the rapidly expanding healthcare diagnostics sector. With contractual obligations already secured and operational capabilities in place, this investment offers substantial growth potential and a significant stake in a proven enterprise.
A seasoned leader in healthcare, Avo Ashkharikian has impressively expanded his family's prosthetics business, Ortho Engineering, achieving $200M in revenue within just five years. As President and CEO, he spearheaded the launch of Outsource and Save, a trailblazing BPO company focused on the healthcare sector. Avo's strategic insight and
A seasoned leader in healthcare, Avo Ashkharikian has impressively expanded his family's prosthetics business, Ortho Engineering, achieving $200M in revenue within just five years. As President and CEO, he spearheaded the launch of Outsource and Save, a trailblazing BPO company focused on the healthcare sector. Avo's strategic insight and leadership extend beyond his executive roles. He serves as a board member for various top healthcare organizations, including Altamed, where his influence helps shape industry standards and enhance community support. His extensive involvement underscores a deep commitment to advancing healthcare and supporting community initiatives.
Stacy Crumpler is a dynamic entrepreneur with extensive experience in business operations, financial management, and corporate governance. As the Co-Owner of Ethos Pathos Logos Clinical Solutions, Stacy has demonstrated expertise in leading operations and driving business growth. Her previous roles include Director of Business Operations
Stacy Crumpler is a dynamic entrepreneur with extensive experience in business operations, financial management, and corporate governance. As the Co-Owner of Ethos Pathos Logos Clinical Solutions, Stacy has demonstrated expertise in leading operations and driving business growth. Her previous roles include Director of Business Operations at Discovery Tox LLC and LRA, where she managed critical financial and operational aspects. Stacy's background is solidified by her education in Finance and Financial Management from the University of Houston, coupled with her early training in Accounting at North Harris Community College. Her strategic vision and ability to manage complex business functions have consistently led to significant business enhancements and revenue growth.
Sonny Patel is an executive leader and entrepreneur with a proven track record in healthcare strategy, business growth, and IT transformations. Currently serving as the President and CEO of Healthquest Diagnostic Laboratory Inc., Sonny has significantly impacted healthcare delivery in chronic illness through innovative testing services a
Sonny Patel is an executive leader and entrepreneur with a proven track record in healthcare strategy, business growth, and IT transformations. Currently serving as the President and CEO of Healthquest Diagnostic Laboratory Inc., Sonny has significantly impacted healthcare delivery in chronic illness through innovative testing services and strategic growth initiatives, driving annual revenues to notable heights. His previous roles include leadership positions at Xelnt Inc. and Molina Healthcare, where he implemented major projects and systems, greatly reducing risks and costs while enhancing service quality and patient satisfaction. Sonny's entrepreneurial spirit is further highlighted by his founding of multiple companies, each becoming leaders in their respective fields. His extensive experience is underpinned by an MBA from Rutgers University, with a concentration in Finance and Management.
Jon Rojas is an accomplished executive with an extensive background in clinical research and development. Over the past two decades, he has spearheaded more than two thousand clinical trials across a broad range of therapeutic areas, including neurology, cardiology, infectious diseases (such as Ebola, Covid-19, and HIV), nephrology, hepat
Jon Rojas is an accomplished executive with an extensive background in clinical research and development. Over the past two decades, he has spearheaded more than two thousand clinical trials across a broad range of therapeutic areas, including neurology, cardiology, infectious diseases (such as Ebola, Covid-19, and HIV), nephrology, hepatology, and oncology. His deep industry knowledge and passionate leadership have not only advanced the field of drug development but have also earned him recognition as a top-ranked executive in the healthcare sector. Known for his empathy and commitment to integrity, honesty, and innovation, Mr. Rojas has consistently inspired and motivated the global clinical drug development community. Through his strategic vision and relentless dedication, he has played a pivotal role in transforming clinical practices and improving patient outcomes worldwide.
Welcome to LabLink Innovations, a distinguished holding company rooted in the vibrant city of Las Vegas, Nevada. At the helm, our organization boasts an exceptional team of both current and former healthcare executives and operators. These seasoned professionals have successfully secured multiple strategic contracts an
304 S. Jones Blvd #4506 Las Vegas, NV 89107
Copyright © 2024 LabLink Innovations - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.